Bristol-Myers Squibb announces new immuno-oncology research collaboration

Bristol-Myers Squibb has announced a new multi-year clinical research collaboration focused on immuno-oncology.

The company is allying with the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) to coordinate and rapidly initiate clinical immuno-oncology studies across the Parker Institute and CRI networks.

Bristol-Myers Squibb will work closely with leading scientists and researchers from the partner organisations to solicit clinical research proposals and coordinate multi-site collaboration studies to pursue challenging cancer research questions.

The aim will be to provide scientists with an ecosystem of advanced translational tools, precision immunotherapies and bioanalytical expertise to inform future studies and generate high-quality data to aid drug development.

This makes Bristol-Myers Squibb the first industry partner to join a collaboration with the Parker Institute and the CRI.

Dr Fouad Namouni, head of oncology development at Bristol-Myers Squibb, said: "Bristol-Myers Squibb is initiating this unique collaboration with a goal of accelerating the identification and development of new treatment options for patients who are facing very serious disease."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.